<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="451">
  <stage>Registered</stage>
  <submitdate>7/09/2005</submitdate>
  <approvaldate>15/11/2005</approvaldate>
  <actrnumber>ACTRN12605000744651</actrnumber>
  <trial_identification>
    <studytitle>The Antioxidant Study</studytitle>
    <scientifictitle>A randomised controlled trial to evaluate the effects of Vitamin E and/or Lipoic acid in people with the Metabolic Syndrome to improve markers of insulin resistance and oxidative stress</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>The Metabolic Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Vitamin E/Lipoic acid for 12 months</interventions>
    <comparator>Placebo for 12 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Markers of Insulin Resistance</outcome>
      <timepoint>Assessed at the conclusion of study at 12 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Reversal of the Metabolic Syndrome</outcome>
      <timepoint>Assessed at the conclusion of study at 12 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Inflammatory markers</outcome>
      <timepoint>Measured at 12 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Metabolic Syndrome</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Type 2 Diabetes</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers.</concealment>
    <sequence>Randomisation was performed using the First generator at www.randomisation.com.  Subjects were randomised using method of randomly permuted blocks.  Blocks of subjects were randomised with stratification for gender.  This was achieved by generating separate randomisation lists for men and women.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>11/01/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>160</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>PO BOX 913, 201 Great King Street Dunedin 9016</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council</fundingname>
      <fundingaddress>Level 3, 110 Stanley Street, Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Patrick Manning</name>
      <address>Department of Medicine
Dunedin Hospital
Dunedin</address>
      <phone>+64 3 4740999</phone>
      <fax />
      <email>PatrickManning@healthotago.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Patrick Manning</name>
      <address>Department of Medicine
Dunedin Hospital
Dunedin</address>
      <phone>+64 3 4740999</phone>
      <fax />
      <email>PatrickManning@healthotago.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>